Literature DB >> 17252256

[Therapy of Paget's disease].

A A Kurth1.   

Abstract

Paget's disease of bone, an often undiagnosed metabolic bone disease, can lead to dramatic skeletal changes with enlargement and bowing of the affected bones. The etiology of this localized bone disease has not yet been determined. Genetic factors and viral infections may be involved. Recently, the treatment options for Paget's disease have been greatly improved due to the development of potent bisphosphonates. These agents inhibit osteoclastic bone resorption and allow the suppression of the excessive bone turnover in Paget's disease. This leads to a stabilization of affected bones and to symptomatic improvements. Treatment should be initiated early after diagnosis to limit the extent of damage. The article gives an overview of recent perspectives on epidemiology, diagnosis, and treatment of the disease according to the new German guidelines for the diagnosis and therapy of Paget's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17252256     DOI: 10.1007/s00132-007-1050-2

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  14 in total

1.  Ibandronate treatment in Paget's disease of bone.

Authors:  A Grauer; S Heichel; J Knaus; E Dosch; R Ziegler
Journal:  Bone       Date:  1999-05       Impact factor: 4.398

2.  Paget's disease of bone; incidence and subclinical forms.

Authors:  D H COLLINS
Journal:  Lancet       Date:  1956-07-14       Impact factor: 79.321

3.  Genetic linkage of Paget disease of the bone to chromosome 18q.

Authors:  J D Cody; F R Singer; G D Roodman; B Otterund; T B Lewis; M Leppert; R J Leach
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

4.  On a Form of Chronic Inflammation of Bones (Osteitis Deformans).

Authors:  J Paget
Journal:  Med Chir Trans       Date:  1877

5.  Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Authors:  E Siris; R S Weinstein; R Altman; J M Conte; M Favus; A Lombardi; K Lyles; H McIlwain; W A Murphy; C Reda; R Rude; M Seton; R Tiegs; D Thompson; J R Tucci; A J Yates; M Zimering
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

6.  Long-term efficacy of intravenous pamidronate in Paget's disease of bone.

Authors:  A Grauer; B Klar; S H Scharla; R Zieglar
Journal:  Semin Arthritis Rheum       Date:  1994-02       Impact factor: 5.532

7.  A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

Authors:  P D Miller; J P Brown; E S Siris; M S Hoseyni; D W Axelrod; P J Bekker
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

8.  [Bisphosphonate therapy of Paget's disease of bone with pamidronate].

Authors:  A Grauer; B Klar; J Knaus; S H Scharla; R Ziegler
Journal:  Med Klin (Munich)       Date:  1996-01-15

9.  Tiludronate therapy for Paget's disease of bone.

Authors:  M R McClung; C K Tou; N H Goldstein; C Picot
Journal:  Bone       Date:  1995-11       Impact factor: 4.398

10.  Frequency and characteristics of familial aggregation of Paget's disease of bone.

Authors:  A A Morales-Piga; J S Rey-Rey; J Corres-González; J M García-Sagredo; G López-Abente
Journal:  J Bone Miner Res       Date:  1995-04       Impact factor: 6.741

View more
  1 in total

1.  [Documentation of outpatient treatment of Paget's disease in Westphalia-Lippe. Descriptive analysis of statutory health insurance data for the year 2005].

Authors:  T Altenhöner; E Dorendorf; O Razum; M Hertrich; C Bonnemann
Journal:  Z Rheumatol       Date:  2009-09       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.